Skip to main content
. Author manuscript; available in PMC: 2021 Nov 6.
Published in final edited form as: Diabetes Obes Metab. 2021 Mar 31;23(6):1351–1360. doi: 10.1111/dom.14347

FIGURE 1.

FIGURE 1

Primary and secondary outcomes in patients with type 2 diabetes discharged on liraglutide and insulin glargine. A, glycated haemoglobin (HbA1c) at baseline, 12 weeks, and 26 weeks. B, Change in body weight from baseline. C, HbA1c < 7% (53 mmol/mol) and no hypoglycaemia or weight loss. D, HbA1c < 7% (53 mmol/mol) and no hypoglycaemia